Attention Neumora Therapeutics Investors: Legal Rights Warning from Levi & Korsinsky
On February 11, 2025, Levi & Korsinsky, LLP announced crucial information for investors in Neumora Therapeutics, Inc. (NASDAQ: NMRA) regarding a class action lawsuit tied to allegations of securities fraud. This class action seeks to recover losses for investors who purchased Neumora shares around September 15, 2023, based on misleading information shared by the company.
The lawsuit covers all individuals and entities that acquired Neumora common stock under the company’s Offering Documents. The key aim of the lawsuit is to hold Neumora responsible for purportedly false statements that significantly impacted investor decisions. Shareholders are invited to follow the link provided by Levi & Korsinsky to gain further information and connect with their legal representatives.
The complaint filed by Levi & Korsinsky alleges that Neumora falsified information and concealed critical data relating to its Phase Three Program. Specific points of concern include:
1. Modifications to BlackThorn’s original Phase Two trial inclusion criteria, which included patients with moderate to severe Major Depressive Disorder (MDD) to show purported improvements using Navacaprant, Neumora’s main therapeutic candidate.
2. Introduction of a pre-specified analysis within the Phase Two statistical analysis plan, aimed at patients suffering from moderate to severe MDD.
3. Insufficient data from Phase Two Trials — the size and gender ratio of the patient population were claimed to be inadequate for making reliable predictions regarding the KOASTAL-1 study results.
As shares of Neumora Therapeutics continue to be scrutinized amid these allegations, investors who faced financial loss during the stipulated timeframe are encouraged to act. The deadline to request appointment as lead plaintiff is April 7, 2025. It is crucial to note that participating as a class member does not necessitate being a lead plaintiff, allowing broader participation in potential recovery efforts.
Levi & Korsinsky emphasizes that there are no out-of-pocket costs for those who qualify as class members. The firm operates under a contingency basis, meaning no fees will be charged unless the case is successful.
Recognized nationally for their prowess in securities litigation, Levi & Korsinsky has over two decades of experience in recovering significant funds for investors who have suffered losses due to corporate misdeeds. They have secured hundreds of millions of dollars for aggrieved shareholders and have been listed repeatedly in top rankings for securities litigation firms in the United States.
For further inquiries, investors can reach out directly to Joseph E. Levi, Esq. or Ed Korsinsky, Esq. by email or phone. Levi & Korsinsky strongly advocates for shareholder rights and safety, ensuring that all legal avenues are explored for their clients' benefit.
Investors from the Neumora Therapeutics, Inc. should not delay in reaching out to seek guidance on their rights and options regarding this unfolding legal situation. As deadlines approach, timely action is crucial in protecting their interests.
Class Action Overview
The lawsuit covers all individuals and entities that acquired Neumora common stock under the company’s Offering Documents. The key aim of the lawsuit is to hold Neumora responsible for purportedly false statements that significantly impacted investor decisions. Shareholders are invited to follow the link provided by Levi & Korsinsky to gain further information and connect with their legal representatives.
Details of the Case
The complaint filed by Levi & Korsinsky alleges that Neumora falsified information and concealed critical data relating to its Phase Three Program. Specific points of concern include:
1. Modifications to BlackThorn’s original Phase Two trial inclusion criteria, which included patients with moderate to severe Major Depressive Disorder (MDD) to show purported improvements using Navacaprant, Neumora’s main therapeutic candidate.
2. Introduction of a pre-specified analysis within the Phase Two statistical analysis plan, aimed at patients suffering from moderate to severe MDD.
3. Insufficient data from Phase Two Trials — the size and gender ratio of the patient population were claimed to be inadequate for making reliable predictions regarding the KOASTAL-1 study results.
As shares of Neumora Therapeutics continue to be scrutinized amid these allegations, investors who faced financial loss during the stipulated timeframe are encouraged to act. The deadline to request appointment as lead plaintiff is April 7, 2025. It is crucial to note that participating as a class member does not necessitate being a lead plaintiff, allowing broader participation in potential recovery efforts.
No Cost to Investors
Levi & Korsinsky emphasizes that there are no out-of-pocket costs for those who qualify as class members. The firm operates under a contingency basis, meaning no fees will be charged unless the case is successful.
Levi & Korsinsky’s Track Record
Recognized nationally for their prowess in securities litigation, Levi & Korsinsky has over two decades of experience in recovering significant funds for investors who have suffered losses due to corporate misdeeds. They have secured hundreds of millions of dollars for aggrieved shareholders and have been listed repeatedly in top rankings for securities litigation firms in the United States.
For further inquiries, investors can reach out directly to Joseph E. Levi, Esq. or Ed Korsinsky, Esq. by email or phone. Levi & Korsinsky strongly advocates for shareholder rights and safety, ensuring that all legal avenues are explored for their clients' benefit.
Investors from the Neumora Therapeutics, Inc. should not delay in reaching out to seek guidance on their rights and options regarding this unfolding legal situation. As deadlines approach, timely action is crucial in protecting their interests.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.